Results 81 to 90 of about 9,412 (255)

Not Your Typical Ulcerative Colitis Patient [PDF]

Modern Medicine
Background: Extraintestinal manifestations (EIMs) of inflammatory bowel diseases (IBDs) are a common and debilitating feature of disease, occurring in up to 40% of patients with IBD.
Teodora SPATARU, Ana STEMATE, Roxana SADAGURSCHI, Lucian NEGREANU   +3 more
doaj   +1 more source

Nonsurgical Treatment of Splenic Abscesses in Patient With Simultaneous Diagnosis of Endocarditis and Crohn's Disease: A Case Report and Literature Review

Clinical Case Reports, Volume 13, Issue 2, February 2025.
ABSTRACT The spleen is one site for septic emboli in cases of IE but in patients with splenic abscess when the patient has a suspicious history of autoimmune diseases, splenic aseptic abscess must be ruled out before splenectomy.
Shiva Shabani
wiley   +1 more source

Simple one-pot green method for large-scale production of mesalamine, an anti-inflammatory agent

Green Processing and Synthesis, 2019
We report a rapid and efficient synthesis protocol for mesalamine via a green approach with 2-chloro-5-nitrobenzoic acid as the starting material, for its large-scale production.
Vijaya Lakshmi C., Katari Naresh Kumar, Jonnalagadda Sreekantha B.   +2 more
doaj   +1 more source

Higher education, professional occupation, and upper socioeconomic status are associated with lower adherence to medications in patients with inflammatory bowel disease

JGH Open, 2019
Background and Aim The literature on medication adherence in patients with inflammatory bowel disease (IBD) is heterogeneous. The present study aimed to identify the rates and predictors of nonadherence to medications in IBD. Methods This cross‐sectional
Sanjeevani K Tomar, Saurabh Kedia, Namrata Singh, Ashish D Upadhyay, Nagesh Kamat, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Saransh Jain, Govind Makharia, Vineet Ahuja   +10 more
doaj   +1 more source

Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis [PDF]

, 2001
S Kane
openalex   +2 more sources

Anti-oxidant and anti-inflammatory potential of different polymer-based mesalamine delayed-release granules in TNBS-induced ulcerative colitis in wistar rats

Saudi Pharmaceutical Journal
Ulcerative colitis (UC) is an inflammatory condition of colon characterized by severe damage to the innermost colon tissues. A number of studies described the use of medication delivery systems based on natural polymers like polysaccharides for the ...
Imtiyaz Ahmed Najar, Archana Sharma, Abdulrahman Alshammari, Thamer H. Albekairi, Metab Alharbi, Taief Ahmad Dar, Zulfkar Latief Qadrie, Atul Kabra, A.M.J Newton, Manish Kumar   +9 more
doaj  

Distal Ulcerative Colitis Refractory to Rectal Mesalamine: Role of Transdermal Nicotine versus Oral Mesalamine

Canadian Journal of Gastroenterology, 2002
BACKGROUND: Distal ulcerative colitis usually responds to treatment with rectal mesalamine, but the management of refractory cases is poorly defined.AIM: To evaluate the possible therapeutic benefit of transdermal nicotine versus oral mesalamine.PATIENTS AND METHODS: Thirty patients with left-sided ulcerative colitis unresponsive to treatment with a ...
Guslandi M, Frego R, Viale E, TESTONI , PIER ALBERTO   +3 more
openaire   +5 more sources

Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials

Drug Design, Development and Therapy, 2014
David Pierce,1 Mary Corcoran,2 Patrick Martin,2 Karen Barrett,1 Susi Inglis,1 Peter Preston,2 Thomas N Thompson,3 Sandra K Willsie3 1Shire, Basingstoke, UK; 2Shire, Wayne, PA, USA; 3PRA International, Lenexa, KS, USA Background: MMX® mesalamine is a
Pierce D, Corcoran M, Martin P, Barrett K, Inglis S, Preston P, Thompson TN, Willsie SK   +7 more
doaj  

A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis

Cells, 2019
IBD98-M is a delayed-release formulation of mesalamine (mesalazine) and SH with a potential therapeutic role in ulcerative colitis (UC). A total of 51 patients with a modified Ulcerative Colitis Disease Activity Index (UCDAI) score of ≥4 and ≤
Gionata Fiorino, Giacomo Carlo Sturniolo, Fabrizio Bossa, Andrea Cassinotti, Antonio Di Sabatino, Paolo Giuffrida, Silvio Danese   +6 more
doaj   +1 more source

Systematic Review and Meta-analysis: Efficacy of Mesalamine in Irritable Bowel Syndrome.

Clinical Gastroenterology and Hepatology, 2023
Vivek C. Goodoory, A. Tuteja, C. Black, A. Ford   +3 more
semanticscholar   +1 more source